Categories: Business

PLTR Investors Have Opportunity to Join Palantir Technologies Inc. Fraud Investigation with the Schall Law Firm

LOS ANGELES–(BUSINESS WIRE)–$PLTRThe Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Palantir Technologies Inc. (“Palantir” or “the Company”) (NASDAQ: PLTR) for violations of the securities laws.

- Advertisement -


- Advertisement -

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Palantir is the subject of a Reuters report published on October 3, 2025. According to the report, an Army memo from September expressed concerns about the battlefield communications platform NGC2, co-developed by the Company and Anduril Industries. The memo claimed the system was flawed and vulnerable to “insider threats, external attacks, and data spillage” as it suffered from “critical deficiencies in fundamental security controls, processes, and governance.”

- Advertisement -

If you are a shareholder who suffered a loss, click here to participate.

- Advertisement -

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at bschall@schallfirm.com.

- Advertisement -

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

- Advertisement -

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

- Advertisement -

Contacts

- Advertisement -

The Schall Law Firm

Brian Schall, Esq.

310-301-3335

info@schallfirm.com
www.schallfirm.com

- Advertisement -
Business Wire

Recent Posts

HUTCHMED Highlights FRUSICA-2 Registration Trial Data to be Presented at the 2025 ESMO Congress

The fruquintinib and sintilimab combination demonstrated significant PFS improvements in advanced renal cell carcinoma patients…

2 hours ago

Qualigen Therapeutics Announces the Official Launch of C10 Cryptocurrency Asset Treasury (DAT) Purchases: Why Is This Pullback the Golden Moment CXC10 Has Been Waiting For?

Carlsbad, CA, Oct. 12, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”)…

2 hours ago

Market Alert: AlphaTON Capital Continues in Growth Mode and Purchases an additional 300,000 TON

Dover, DE, Oct. 12, 2025 (GLOBE NEWSWIRE) -- AlphaTON Capital Corp. (Nasdaq: ATON) stated that…

5 hours ago

BNB News: Sparkvia AI Launches $SPARK Presale on BNB ChainBringing The First AI-Powered Writing Platform to BNB Ecosystem

VALLETTA, Malta, Oct. 12, 2025 (GLOBE NEWSWIRE) -- Sparkvia AI announces the launch of the…

5 hours ago

Jefferies Provides Letter from Its CEO and President Regarding Point Bonita Capital and First Brands Group

NEW YORK--(BUSINESS WIRE)--Jefferies Financial Group, Inc. (NYSE: JEF) (“Jefferies”) announced today that is has posted…

5 hours ago

China’s Central Academy of Fine Arts Launches AI-Powered Chatbot to Enhance Global Website Experience

BEIJING, Oct. 10, 2025 /PRNewswire/ -- The Central Academy of Fine Arts (CAFA), China's most prestigious and…

5 hours ago